<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00131066</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP085</org_study_id>
    <nct_id>NCT00131066</nct_id>
  </id_info>
  <brief_title>Long-Term Follow-Up Study of Psoriasis Patients</brief_title>
  <official_title>Long-Term Safety Follow-Up Study of Psoriasis Patients Who Have Received MEDI-507</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety and profile of psoriasis
      patients who have completed participation in a previous study and who received treatment with
      MEDI-507.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the long-term safety and lymphocyte repletion profile of psoriasis
      patients who have completed participation in a previous study and who received treatment with
      MEDI-507. Patients must have had an ALC &gt; 30% lower than baseline (defined as baseline prior
      to any MEDI-507 exposure); or an absolute CD4 count of &lt; 250 cells/uL. This study will also
      evaluate the development and durability of anti-MEDI-507 antibodies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">200</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Follow up from previous treatment with MEDI-507</intervention_name>
    <description>There will be no investigational drugs administered under this protocol.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient has previously completed participation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has previously completed participation (i.e., completed per protocol,
             including any long term follow-up; or discontinued from the study due to withdrawal of
             consent, loss to follow-up, or other reason) in a Medimmune, Inc. study of MEDI-507 in
             psoriasis in which they received MEDI-507 (or placebo for patients who participated in
             a blinded placebo-controlled study of MEDI-507, and for whom the treatment assignment
             in that study has not been unblinded at the time of entry into this study)

          -  The patient had an absolute lymphocyte count (ALC) &gt; 30% lower than baseline (defined
             as baseline prior to any MEDI-507 exposure; or, for patients whose treatment
             assignments have not been unblinded at the time of entry into this study, drug
             exposure) at his/her final visit (excluding any long-term follow-up visits) in the
             most recent Medimmune, Inc. study in which the patient participated; or the patient
             had an absolute CD4 count of &lt; 250 cells/uL at his/her final visit (including any
             protocol-specific long-term follow up) in the most recent Medimmune, Inc. study in
             which the patient participated.

          -  Written informed consent obtained from the patient

        Exclusion Criteria:

          -  There are no exclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara White, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Research Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherry Creek Dermatology</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Dermatology, Vein &amp; Research Center, LLC</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Future Care Studies</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University, Dermatology Clinical Trials Unit</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Kinetics</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaur Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>185</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Centre Ville</name>
      <address>
        <city>Liege</city>
        <zip>4020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital District Health Authority, QE II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H1V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research</name>
      <address>
        <city>Montreal</city>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu/Clinque Dermatologique</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>F-44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Saint-Louis Service de Dermatologie 1</name>
      <address>
        <city>Paris</city>
        <zip>F-75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Haut Leveque CHU Sud -Service de Dermatologie</name>
      <address>
        <city>Pessac</city>
        <zip>F-33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitataskilinkum der TU Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Hautklinik</name>
      <address>
        <city>Dusseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum de Johann - Wolfgang Goethe Universitate Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Urban, Dermatologie</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Hautklinik</name>
      <address>
        <city>Tubingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum/Universiteit van Amsterdam (AMC/UvA)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2005</study_first_submitted>
  <study_first_submitted_qc>August 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2005</study_first_posted>
  <last_update_submitted>September 18, 2008</last_update_submitted>
  <last_update_submitted_qc>September 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Barbara White</name_title>
    <organization>MedImmune Inc.</organization>
  </responsible_party>
  <keyword>Previously enrolled on a MEDI-507 for psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

